Skip to main
ABVX

Abivax SA (ABVX) Stock Forecast & Price Target

Abivax SA (ABVX) Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 33%
Buy 58%
Hold 0%
Sell 8%
Strong Sell 0%

Bulls say

Abivax is seen as a promising company with a unique approach to treating chronic inflammatory diseases through the use of obefazimod, a novel drug candidate that targets the body's natural regulatory mechanisms. Their Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis have shown positive results with high efficacy rates and limited side effects. With plans for combination development and potential interest from large pharmaceutical companies, Abivax has the potential for significant growth in a growing market, making it a solid investment opportunity.

Bears say

Abivax is facing intense competition from biosimilars, new targets, and combination therapies while only receiving limited short interest for its shares. Furthermore, the market growth rate is rapid and appears to be driven by environmental factors, and although the company's initial focus is on inflammatory bowel diseases with a combined value of approximately $23 billion, it has little to no experience in commercializing its products and its drug candidate, obefazimod, has shown concerning safety signals in its neurologic adverse events.

Abivax SA (ABVX) has been analyzed by 12 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 58% recommend Buy, 0% suggest Holding, 8% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Abivax SA and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Abivax SA (ABVX) Forecast

Analysts have given Abivax SA (ABVX) a Buy based on their latest research and market trends.

According to 12 analysts, Abivax SA (ABVX) has a Buy consensus rating as of May 23, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $136.42, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $136.42, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Abivax SA (ABVX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.